In vitro and in vivo production of vascular endothelial growth factor by chronic lymphocytic leukemia cells

Blood

Volumn 96, Issue 9, 2000, Pages 3181-3187

  Chen, Haijuan ^a   Treweeke, Andy T ^a   West, Dave C ^a   Till, Kathleen J ^a   Cawley, John C ^a   Zuzel, Mirko ^a   Toh, Cheng H ^a  

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

VASCULOTROPIN;

ANGIOGENESIS; ARTICLE; CELL PROLIFERATION; CHRONIC LYMPHATIC LEUKEMIA; ENDOTHELIUM CELL; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; LEUKEMIA CELL; NEOVASCULARIZATION (PATHOLOGY); PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SOLID TUMOR;

EID: 0034329298     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v96.9.3181.h8003181_3181_3187     Document Type: Article

References (49)

1. Blood vessel formation: What is its molecular basis?
2. Clinical applications of research on angiogenesis
3. Tumor angiogenesis
4. Angiogenesis factors
5. Expression of vascular endothelial growth factor, its receptor, and other angiogenic factors in human breast cancer
6. Significance of vascular endothelial growth factor messenger RNA expression in primary lung cancer
7. Expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in adenocarcinomas of the gastrointestinal tract
8. Androgens regulate vascular endothelial growth factor content in normal and malignant prostatic tissue
9. Vascular endothelial growth factor is a potential tumour angiogenesis factor in human gliomas in vivo
10. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumor growth in vivo
11. Inhibition of vascular endothelial-cell growth-factor activity by an endogenously encoded soluble receptor
12. Glioblastoma growth inhibited in-vivo by a dominant-negative Flk-1 mutant
13. Angiogenesis spectrum in the stroma of B-cell non-Hodgkin's lymphoma: An immunohistochemical and ultrastructural study
14. Spectrum of tumor angiogenesis in the bone marrow of children with acute lymphoblastic leukemia
15. Bone marrow angiogenesis and progression in multiple myeloma
16. Abnormal angiogenesis in the bone marrow of patients with hairy cell leukemia (HCL)
17. National institute-sponsored working group guidelines for chronic lymphocytic leukemia: Revised guidelines for diagnosis and treatment
18. Evidence for abnormal angiogenesis in the bone marrow of patients with B-cell chronic lymphocytic leukemia (CLL)
19. Clinico-prognostic implications of increased levels of serum vascular endothelial growth factor in B-CLL chronic lymphocytic leukemia
20. Quantitative analysis of vascular endothelial growth factor expression in chronic lymphocytic leukemia
21. Expression of vascular endothelial growth factor in lymphomas and Castleman's disease
22. Vascular endothelial growth factor induced by hypoxia, a mediator hypoxia-initiated angiogenesis
23. Induction of vascular endothelial growth factor by hypoxia is modulated by a phosphatidylinositol 3-kinase/Akt signaling pathway in Ha-ras-transformed cells through a hypoxia inducible factor-1 transcriptional element
24. Accessory cells mediate hairy-cell proliferation by mechanism(s) involving both adhesion and TNF-α secretion
25. Tumor angiogenesis correlates with metastasis in invasive prostate cancer
26. Angiogenesis induced by degradation products of hyaluronic-acid
27. Tumor-derived expression of vascular endothelial growth factor is a critical factor in tumor expansion and vascular function
28. Role of protein kinase C isoforms in phorbol ester-induced vascular endothelial growth factor expression in human glioblastoma cells
29. Peripheral blood T lymphocytes and lymphocytes infiltrating human cancer express vascular endothelial growth factor: A potential role for T cells in angiogenesis
30. Regulation of the expression of the VEGF/VPS and its receptors: Role in tumor angiogenesis
31. Release of the angiogenic cytokine vascular endothelial growth factor (VEGF) from platelets: Significance for VEGF measurements and cancer biology
32. The human gene for vascular endothelial growth factor, multiple protein forms are encoded through alternative exon splicing
33. The vascular endothelial growth factor family: Identification of a fourth molecular species and characterization of alternative splicing of RNA
34. VEGF145, a secreted vascular endothelial growth factor isoform that binds to extracellular matrix
35. Human vascular permeability factor: Isolation from U937 cells
36. Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid
37. Vascular permeability factor, an endothelial cell mitogen related to platelet-derived growth factor
38. Amino acid and cDNA sequence of a vascular endothelial cell mitogen homologous to platelet-derived growth factor
39. Vascular endothelial growth factor is a secreted angiogenic mitogen
40. Vascular endothelial growth factor stimulates tyrosine phosphorylation and recruitment to new focal adhesions of focal adhesion kinase and paxillin in endothelial cells
41. Vascular endothelial growth factor acts as a survival factor for newly formed retinal vessels and has implications for retinopathy of prematurity
42. Conditional switching of vascular endothelial growth factor (VEGF) expression in tumors: Induction of endothelial cell shedding and regression of hemangioblastoma-like vessels by VEGF withdrawal
43. Expression of multiple angiogeneic cytokines in cultured normal human prostate epithelial cells: Predominance of vascular endothelial growth factor
44. Angiogenesis by fibroblast growth factor 4 is mediated through an autocrine up-regulation of vascular endothelial growth factor expression
45. Vascular endothelial growth factor (VEGF) isoforms-differential deposition into the subepithelial extracellular matrix and bioactivity of extracellular matrix-bound VEGF
46. Vascular endothelial growth factor (VEGF) and its receptors
47. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis
48. Increased serum levels of vascular endothelial growth factor predict risk of progression in early B-cell chronic lymphocytic leukaemia
49. Low levels of vascular endothelial growth factor (VEGF) in cells of patients with chronic lymphoid leukemia (CLL) correlate with survival, particularly in patients with low β2-microglobulin (β2M) levels